Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
318 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Tuberculosis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Tuberculosis - Pipeline Review, H2 2014', provides an overview of the Tuberculosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tuberculosis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Tuberculosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Tuberculosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Tuberculosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Tuberculosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Tuberculosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Tuberculosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 Introduction 5 Tuberculosis Overview 6 Therapeutics Development 7 Tuberculosis - Therapeutics under Development by Companies 9 Tuberculosis - Therapeutics under Investigation by Universities/Institutes 15 Tuberculosis - Pipeline Products Glance 18 Tuberculosis - Products under Development by Companies 22 Tuberculosis - Products under Investigation by Universities/Institutes 29 Tuberculosis - Companies Involved in Therapeutics Development 33 Tuberculosis - Therapeutics Assessment 89 Drug Profiles 100 Tuberculosis - Recent Pipeline Updates 274 Tuberculosis - Dormant Projects 287 Tuberculosis - Discontinued Products 289 Tuberculosis - Product Development Milestones 290 Appendix 300
List of Tables Number of Products under Development for Tuberculosis, H2 2014 24 Number of Products under Development for Tuberculosis - Comparative Analysis, H2 2014 25 Number of Products under Development by Companies, H2 2014 27 Number of Products under Development by Companies, H2 2014 (Contd..1) 28 Number of Products under Development by Companies, H2 2014 (Contd..2) 29 Number of Products under Development by Companies, H2 2014 (Contd..3) 30 Number of Products under Development by Companies, H2 2014 (Contd..4) 31 Number of Products under Investigation by Universities/Institutes, H2 2014 33 Comparative Analysis by Late Stage Development, H2 2014 35 Comparative Analysis by Clinical Stage Development, H2 2014 36 Comparative Analysis by Early Stage Development, H2 2014 37 Comparative Analysis by Unknown Stage Development, H2 2014 38 Products under Development by Companies, H2 2014 39 Products under Development by Companies, H2 2014 (Contd..1) 40 Products under Development by Companies, H2 2014 (Contd..2) 41 Products under Development by Companies, H2 2014 (Contd..3) 42 Products under Development by Companies, H2 2014 (Contd..4) 43 Products under Development by Companies, H2 2014 (Contd..5) 44 Products under Development by Companies, H2 2014 (Contd..6) 45 Products under Investigation by Universities/Institutes, H2 2014 46 Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 47 Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 48 Products under Investigation by Universities/Institutes, H2 2014 (Contd..3) 49 Tuberculosis - Pipeline by Abera Bioscience AB, H2 2014 50 Tuberculosis - Pipeline by Achillion Pharmaceuticals, Inc., H2 2014 51 Tuberculosis - Pipeline by Anacor Pharmaceuticals, Inc., H2 2014 52 Tuberculosis - Pipeline by Archivel Farma S.L., H2 2014 53 Tuberculosis - Pipeline by AstraZeneca PLC, H2 2014 54 Tuberculosis - Pipeline by BioDiem Ltd, H2 2014 55 Tuberculosis - Pipeline by Biomar Microbial Technologies, H2 2014 56 Tuberculosis - Pipeline by Bioversys AG, H2 2014 57 Tuberculosis - Pipeline by Cellceutix Corporation, H2 2014 58 Tuberculosis - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H2 2014 59 Tuberculosis - Pipeline by Crucell N.V., H2 2014 60 Tuberculosis - Pipeline by Dafra Pharma International Ltd., H2 2014 61 Tuberculosis - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 62 Tuberculosis - Pipeline by Eisai Co., Ltd., H2 2014 63 Tuberculosis - Pipeline by Eli Lilly and Company, H2 2014 64 Tuberculosis - Pipeline by Ensoltek Co., Ltd., H2 2014 65 Tuberculosis - Pipeline by EpiVax, Inc., H2 2014 66 Tuberculosis - Pipeline by FIT Biotech Oyj, H2 2014 67 Tuberculosis - Pipeline by GangaGen Inc., H2 2014 68 Tuberculosis - Pipeline by GlaxoSmithKline plc, H2 2014 69 Tuberculosis - Pipeline by GlobalAcorn, H2 2014 70 Tuberculosis - Pipeline by Globeimmune, Inc., H2 2014 71 Tuberculosis - Pipeline by Imaxio SA, H2 2014 72 Tuberculosis - Pipeline by Immunitor, Inc., H2 2014 73 Tuberculosis - Pipeline by ImmunoBiology Ltd., H2 2014 74 Tuberculosis - Pipeline by Immunovaccine, Inc., H2 2014 75 Tuberculosis - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014 76 Tuberculosis - Pipeline by Johnson & Johnson, H2 2014 77 Tuberculosis - Pipeline by Lipotek Pty Ltd., H2 2014 78 Tuberculosis - Pipeline by Medisyn Technologies, Inc., H2 2014 79 Tuberculosis - Pipeline by Microbion Corporation, H2 2014 80 Tuberculosis - Pipeline by Microbiotix, Inc., H2 2014 81 Tuberculosis - Pipeline by Novartis AG, H2 2014 82 Tuberculosis - Pipeline by Orchid Chemicals & Pharmaceuticals Ltd, H2 2014 83 Tuberculosis - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 84 Tuberculosis - Pipeline by Pharminox Limited, H2 2014 85 Tuberculosis - Pipeline by Piramal Enterprises Limited, H2 2014 86 Tuberculosis - Pipeline by Prokarium Ltd., H2 2014 87 Tuberculosis - Pipeline by Sanofi, H2 2014 88 Tuberculosis - Pipeline by Sanofi Pasteur SA, H2 2014 89 Tuberculosis - Pipeline by Sarepta Therapeutics, Inc., H2 2014 90 Tuberculosis - Pipeline by Seek, H2 2014 91 Tuberculosis - Pipeline by Shanghai Zerun Biotechnology Co., Ltd., H2 2014 92 Tuberculosis - Pipeline by Snowdon Inc., H2 2014 93 Tuberculosis - Pipeline by Sphaera Pharma Pvt. Ltd., H2 2014 94 Tuberculosis - Pipeline by Syntrix Biosystems, Inc., H2 2014 95 Tuberculosis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 96 Tuberculosis - Pipeline by TetraLogic Pharmaceuticals, H2 2014 97 Tuberculosis - Pipeline by Therametrics holding AG, H2 2014 98 Tuberculosis - Pipeline by Transgene SA, H2 2014 99 Tuberculosis - Pipeline by TVAX Biomedical, Inc., H2 2014 100 Tuberculosis - Pipeline by Vaccibody AS, H2 2014 101 Tuberculosis - Pipeline by Vakzine Projekt Management GmbH, H2 2014 102 Tuberculosis - Pipeline by Vaxil Bio Therapeutics Ltd., H2 2014 103 Tuberculosis - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2014 104 Tuberculosis - Pipeline by Vichem Chemie Research Ltd., H2 2014 105 Assessment by Monotherapy Products, H2 2014 106 Number of Products by Stage and Target, H2 2014 109 Number of Products by Stage and Mechanism of Action, H2 2014 112 Number of Products by Stage and Route of Administration, H2 2014 114 Number of Products by Stage and Molecule Type, H2 2014 116 Tuberculosis Therapeutics - Recent Pipeline Updates, H2 2014 291 Tuberculosis - Dormant Projects, H2 2014 304 Tuberculosis - Discontinued Products, H2 2014 306
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
